When should the need for continued treatment with the Aspire Pharma Ltd product risedronate sodium 35 mg film-coated tablets be re-evaluated?

Continued treatment with the Aspire Pharma Ltd product risedronate sodium 35 mg film-coated tablets should be re-evaluated periodically according to each patient's benefits and potential risks, particularly after 5 or more years of use, as the optimal duration of bisphosphonate treatment for osteoporosis has not been established.